These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10407249)

  • 1. Unobserved covariates in the two-sample comparison of survival times: a maximum efficiency robust test.
    Broët P; Moreau T; Lellouch J; Asselain B
    Stat Med; 1999 Jul; 18(14):1791-800; discussion 1801. PubMed ID: 10407249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frailty models and rank tests.
    Oakes D; Jeong JH
    Lifetime Data Anal; 1998; 4(3):209-28. PubMed ID: 9787603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of trial duration on the bias of the estimated treatment effect in clinical trials when individual heterogeneity is ignored.
    Cécilia-Joseph E; Auvert B; Broët P; Moreau T
    Biom J; 2015 May; 57(3):371-83. PubMed ID: 25597640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonproportional hazards and unobserved heterogeneity in clustered survival data: When can we tell the difference?
    Balan TA; Putter H
    Stat Med; 2019 Aug; 38(18):3405-3420. PubMed ID: 31050028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of nested frailties into semiparametric multi-state models.
    Rotolo F; Rondeau V; Legrand C
    Stat Med; 2016 Feb; 35(4):609-21. PubMed ID: 26381148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of unmeasured heterogeneity in the linear transformation model for censored data.
    Zhang B; Li Y; Betensky RA
    Lifetime Data Anal; 2006 Jun; 12(2):191-203. PubMed ID: 16817004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The two-sample problem with induced dependent censorship.
    Huang Y
    Biometrics; 1999 Dec; 55(4):1108-13. PubMed ID: 11315055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighted Lindley frailty model: estimation and application to lung cancer data.
    Mota A; Milani EA; Calsavara VF; Tomazella VLD; Leão J; Ramos PL; Ferreira PH; Louzada F
    Lifetime Data Anal; 2021 Oct; 27(4):561-587. PubMed ID: 34331190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The power of testing a semi-parametric shared gamma frailty parameter in failure time data.
    Rahgozar M; Faghihzadeh S; Rouchi GB; Peng Y
    Stat Med; 2008 Sep; 27(21):4328-39. PubMed ID: 18551516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiparametric regression analysis of failure time data with dependent interval censoring.
    Chen CM; Shen PS
    Stat Med; 2017 Sep; 36(21):3398-3411. PubMed ID: 28585322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation program for estimating statistical power of Cox's proportional hazards model assuming no specific distribution for the survival time.
    Akazawa K; Nakamura T; Moriguchi S; Shimada M; Nose Y
    Comput Methods Programs Biomed; 1991 Jul; 35(3):203-12. PubMed ID: 1935013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introducing a new estimator and test for the weighted all-cause hazard ratio.
    Ozga AK; Rauch G
    BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival models induced by zero-modified power series discrete frailty: Application with a melanoma data set.
    Molina KC; Calsavara VF; Tomazella VD; Milani EA
    Stat Methods Med Res; 2021 Aug; 30(8):1874-1889. PubMed ID: 33955295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.